Clinical Trials · NCT05793450
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 20
- Start date
- May 2023
- Locations
- 1 site, China
- Primary endpoint
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362